Skip to main content
. 2021 Jan 4;131(1):e138986. doi: 10.1172/JCI138986

Figure 2. Blocking SEV secretion from ECs delays AML progression.

Figure 2

(A) The experimental design. (BF) Survival curves of AML recipients with different genotypes. Cdh5-Cre;Vps33bfl/fl (B), Lepr-Cre;Vps33bfl/fl (C), Osx-CreER;Vps33bfl/fl (D), Pf4-Cre;Vps33bfl/fl (E), and Tcf21-CreER;Vps33bfl/fl (F) are shown (n = 5–8; **P < 0.01, ***P < 0.001, log-rank test). Experiments were conducted 3 times for validation.